Drug-resistant tuberculosis in Central Mozambique: the role of a rapid genotypic susceptibility testing. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Namburete, Evangelina; Tivane, Inês; Lisboa, Miguelhete; Passeri, Margarida; Pocente, Renata; Ferro, Josefo; Harrison, Lee; Bollela, Valdes
• Is Part Of: BMC infectious diseases. Volume 16:Issue 1(2016)
• Page Start: 1
• Page End: 6
• Publication Date: 2016-12
• Subjects: Tuberculosis -- Molecular diagnosis -- Mozambique; Communicable diseases -- Periodicals; Sexually Transmitted Diseases -- Periodicals; 616.905
• DOI: 10.1186/s12879-016-1766-x
• Languages: English
• ISSNs: 1471-2334

Abstract

Abstract Background Genotypic molecular testing may be very helpful for tuberculosis (TB) drug-resistance surveillance and for treatment guidance in low resource settings. Methods Descriptive analysis ofM. tuberculosis isolates from Beira Central Hospital, Mozambique, during 2014–2015. Genotype MTBDRplus and MTBDRsl were used and patient medical records reviewed. To explore genotypic susceptibility profile ofMycobacterium tuberculosis, to first and second line drugs (SLD) in Beira Mozambique. Results Of 155 isolates, 16.1 % (25) were multidrug resistant (MDR), 8.4 % (13) isoniazid-monoresistant and 1.3 % (2) rifampicin-monoresistant. Among MDR-TB, 22.2 % showed primary and 77.8 % represented acquired resistance. The majority of patients with drug resistance had a history of previous TB treatment. Among 125 isolates tested for ethambutol and SLD, 7.2 % (9) were resistant to ethambutol, 4.8 % (6) to fluoroquinolones and 0.8 % (1) to ethambutol and fluoroquinolones. Resistance to injectable SLD was not detected. Conclusions As far as we know this is the first report of a genotypic testing used to provide information about SLD resistance in Mozambique, where phenotypic susceptibility testing is usually unavailable. Extensively drug resistant TB was not detected in this isolates from Beira Mozambique.